We are live on ! Find out more
ELTX icon

Elicio Therapeutics

30 hedge funds and large institutions have $20.9M invested in Elicio Therapeutics in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

40,750% more call options, than puts

Call options by funds: $1.63M | Put options by funds: $4K

1,212% more capital inflows, than outflows

Capital inflows: $5.16M | Capital outflows: $394K

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

43% more funds holding

Funds holding: 21 → 30 (+9)

2.66% more ownership

Funds ownership: 9.07% → 11.73% (+2.7%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
30
Holders Change
+9
Holders Change %
+42.86%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
9
Reduced
2
Closed
3
Calls
$1.63​M
Puts
$4​K
Net Calls
+$1.63​M
Net Calls Change
+$646​K

ELTX Hedge Fund Activity: Q3 2025 in Review

30 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q3 2025, worth a combined $20.9M — up 87% from $11.2M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ELTX positions and 3 closed out — a net gain of 9 holders — while 9 added to existing stakes and 2 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.5M. The largest seller was CM Management, cutting an estimated $192K.

  • 30 institutional investors held Elicio Therapeutics (ELTX) as of Q3 2025, up from 21 in Q2 2025.
  • Funds reported $20.9M of Elicio Therapeutics stock for Q3 2025, up 87% quarter-over-quarter.
  • 12 funds opened new Elicio Therapeutics positions in Q3 2025 and 3 closed out, a net change of +9 holders.
  • The largest Elicio Therapeutics buyer in Q3 2025 was Balyasny Asset Management, an estimated $1.5M added.
  • The largest Elicio Therapeutics seller in Q3 2025 was CM Management, an estimated $192K sold.

Based on aggregated 13F filings for Q3 2025.